Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 165

1.

Hepatocellular carcinoma occurrence does not differ between interferon-based and interferon-free treatment with liver histological assessment.

Tahata Y, Sakamori R, Urabe A, Yamada R, Ohkawa K, Hiramatsu N, Hagiwara H, Oshita M, Hijioka T, Tamura S, Imai Y, Kodama T, Hikita H, Tatsumi T, Takehara T.

Hepatol Res. 2019 Nov 20. doi: 10.1111/hepr.13454. [Epub ahead of print]

PMID:
31747479
2.

Significance of in vitro photodynamic cytodiagnosis using 5-aminolevulinic acid in solid pancreatic tumors extracted by endoscopic ultrasound-guided fine-needle aspiration.

Hirao M, Hosui A, Mimura A, Tanimoto T, Onishi K, Kusumoto Y, Yamaguchi T, Yamada T, Miwa H, Hiramatsu N.

Photodiagnosis Photodyn Ther. 2019 Oct 16:101581. doi: 10.1016/j.pdpdt.2019.101581. [Epub ahead of print]

PMID:
31629090
3.

ER membrane protein complex is required for the insertions of late-synthesized transmembrane helices of Rh1 in Drosophila photoreceptors.

Hiramatsu N, Tago T, Satoh T, Satoh AK.

Mol Biol Cell. 2019 Nov 1;30(23):2890-2900. doi: 10.1091/mbc.E19-08-0434. Epub 2019 Sep 25.

4.

Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response.

Yamada R, Hiramatsu N, Oze T, Urabe A, Tahata Y, Morishita N, Kodama T, Hikita H, Sakamori R, Yakushijin T, Yamada A, Hagiwara H, Mita E, Oshita M, Itoh T, Fukui H, Inui Y, Hijioka T, Inada M, Katayama K, Tamura S, Inoue A, Imai Y, Tatsumi T, Hamasaki T, Hayashi N, Takehara T.

Hepatol Res. 2019 May;49(5):570-578. doi: 10.1111/hepr.13310. Epub 2019 Feb 6.

PMID:
30623521
5.

Long-Term Zinc Supplementation Improves Liver Function and Decreases the Risk of Developing Hepatocellular Carcinoma.

Hosui A, Kimura E, Abe S, Tanimoto T, Onishi K, Kusumoto Y, Sueyoshi Y, Matsumoto K, Hirao M, Yamada T, Hiramatsu N.

Nutrients. 2018 Dec 10;10(12). pii: E1955. doi: 10.3390/nu10121955.

6.

Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C.

Tahata Y, Sakamori R, Urabe A, Morishita N, Yamada R, Yakushijin T, Hiramatsu N, Doi Y, Kaneko A, Hagiwara H, Yamada Y, Hijioka T, Inada M, Tamura S, Imai Y, Furuta K, Kodama T, Hikita H, Tatsumi T, Takehara T.

Hepatol Commun. 2018 Aug 6;2(8):884-892. doi: 10.1002/hep4.1206. eCollection 2018 Aug.

7.

Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.

Ashida K, Iwakiri K, Hiramatsu N, Sakurai Y, Hori T, Kudou K, Nishimura A, Umegaki E.

World J Gastroenterol. 2018 Apr 14;24(14):1550-1561. doi: 10.3748/wjg.v24.i14.1550.

8.

Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.

Matsumoto A, Nishiguchi S, Enomoto H, Kang JH, Tanaka Y, Shinkai N, Kurosaki M, Enomoto M, Kanda T, Yokosuka O, Yatsuhashi H, Nagaoka S, Okuse C, Kagawa T, Mine T, Takaguchi K, Saito S, Hino K, Ikeda F, Sakisaka S, Morihara D, Miyase S, Tsuge M, Chayama K, Hiramatsu N, Suzuki Y, Murata K, Tanaka E.

J Gastroenterol. 2018 Feb;53(2):247-257. doi: 10.1007/s00535-017-1360-z. Epub 2017 Jun 20.

PMID:
28634723
9.

A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis.

Iwakiri K, Sakurai Y, Shiino M, Okamoto H, Kudou K, Nishimura A, Hiramatsu N, Umegaki E, Ashida K.

Therap Adv Gastroenterol. 2017 Jun;10(6):439-451. doi: 10.1177/1756283X17705329. Epub 2017 Apr 25.

10.

Psychopharmacology of combined activation of the serotonin1A and σ1 receptors.

Ago Y, Hasebe S, Hiramatsu N, Hashimoto H, Takuma K, Matsuda T.

Eur J Pharmacol. 2017 Aug 15;809:172-177. doi: 10.1016/j.ejphar.2017.05.035. Epub 2017 May 18. Review.

PMID:
28529139
11.

Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment.

Kai Y, Hikita H, Morishita N, Murai K, Nakabori T, Iio S, Hagiwara H, Imai Y, Tamura S, Tsutsui S, Naito M, Nishiuchi M, Kondo Y, Kato T, Suemizu H, Yamada R, Oze T, Yakushijin T, Hiramatsu N, Sakamori R, Tatsumi T, Takehara T.

Sci Rep. 2017 Jan 30;7:41660. doi: 10.1038/srep41660.

12.

A case of gastric mixed adenoneuroendocrine carcinoma with difficulty in diagnosis before endoscopic submucosal dissection.

Sakatani A, Shinzaki S, Hayashi Y, Maekawa A, Hiyama S, Yakushijin T, Tatsumi T, Iijima H, Hiramatsu N, Morii E, Takehara T.

Nihon Shokakibyo Gakkai Zasshi. 2016;113(11):1909-1915. Review. Japanese.

PMID:
27829603
13.

Ultra-deep sequencing analysis of resistance-associated variants during retreatment with simeprevir-based triple therapy after failure of telaprevir-based triple therapy in patients with genotype 1 hepatitis C virus infection.

Morishita N, Hiramatsu N, Oze T, Urabe A, Tahata Y, Yamada R, Yakushijin T, Hosui A, Iio S, Yamada A, Hagiwara H, Mita E, Yamada Y, Ito T, Inada M, Katayama K, Yabuuchi I, Imai Y, Hikita H, Sakamori R, Yoshida Y, Tatsumi T, Hayashi N, Takehara T.

Hepatol Res. 2017 Jul;47(8):773-782. doi: 10.1111/hepr.12817. Epub 2016 Oct 26.

PMID:
27593967
14.

Rubicon inhibits autophagy and accelerates hepatocyte apoptosis and lipid accumulation in nonalcoholic fatty liver disease in mice.

Tanaka S, Hikita H, Tatsumi T, Sakamori R, Nozaki Y, Sakane S, Shiode Y, Nakabori T, Saito Y, Hiramatsu N, Tabata K, Kawabata T, Hamasaki M, Eguchi H, Nagano H, Yoshimori T, Takehara T.

Hepatology. 2016 Dec;64(6):1994-2014. doi: 10.1002/hep.28820. Epub 2016 Oct 21.

PMID:
27637015
15.

Signal transducer and activator of transcription 5 plays a crucial role in hepatic lipid metabolism through regulation of CD36 expression.

Hosui A, Tatsumi T, Hikita H, Saito Y, Hiramatsu N, Tsujii M, Hennighausen L, Takehara T.

Hepatol Res. 2017 Jul;47(8):813-825. doi: 10.1111/hepr.12816. Epub 2016 Oct 18.

PMID:
27593674
16.

A case report of pancreatic metastasis from synovial sarcoma successfully treated by metastasectomy with adjuvant chemotherapy.

Makino Y, Shigekawa M, Kegasawa T, Suda T, Yoshioka T, Iwahashi K, Ikezawa K, Sakamori R, Yakushijin T, Kajihara J, Tomimaru Y, Eguchi H, Imura Y, Outani H, Naka N, Honma K, Morii E, Tatsumi T, Hiramatsu N, Takehara T.

Medicine (Baltimore). 2016 Sep;95(39):e4789. doi: 10.1097/MD.0000000000004789.

17.

CD14+ monocyte-derived galectin-9 induces natural killer cell cytotoxicity in chronic hepatitis C.

Nishio A, Tatsumi T, Nawa T, Suda T, Yoshioka T, Onishi Y, Aono S, Shigekawa M, Hikita H, Sakamori R, Okuzaki D, Fukuhara T, Matsuura Y, Hiramatsu N, Takehara T.

Hepatology. 2017 Jan;65(1):18-31. doi: 10.1002/hep.28847. Epub 2016 Nov 5.

PMID:
27640362
18.

The safety and benefit of pancreatic juice cytology under ERCP in IPMN patients.

Yoshioka T, Shigekawa M, Yamai T, Suda T, Kegasawa T, Iwahashi K, Ikezawa K, Sakamori R, Yakushijin T, Hiramatsu N, Tatsumi T, Takehara T.

Pancreatology. 2016 Nov - Dec;16(6):1020-1027. doi: 10.1016/j.pan.2016.08.009. Epub 2016 Aug 18.

PMID:
27567445
19.

Involvement of GABAA receptors in 5-HT1A and σ1 receptor synergism on prefrontal dopaminergic transmission under circulating neurosteroid deficiency.

Ago Y, Hasebe S, Hiramatsu N, Mori K, Watabe Y, Onaka Y, Hashimoto H, Takuma K, Matsuda T.

Psychopharmacology (Berl). 2016 Sep;233(17):3125-34. doi: 10.1007/s00213-016-4353-3. Epub 2016 Jun 23.

PMID:
27339616
20.

Sodium taurocholate cotransporting polypeptide inhibition efficiently blocks hepatitis B virus spread in mice with a humanized liver.

Nakabori T, Hikita H, Murai K, Nozaki Y, Kai Y, Makino Y, Saito Y, Tanaka S, Wada H, Eguchi H, Takahashi T, Suemizu H, Sakamori R, Hiramatsu N, Tatsumi T, Takehara T.

Sci Rep. 2016 Jun 9;6:27782. doi: 10.1038/srep27782.

Supplemental Content

Loading ...
Support Center